Burgues et al evaluated the response of men with hypogonadotropic hypogonadism to subcutaneous injections of follicle stimulating hormone (FSH) and human chorionic gonadogrophin (HCG). This was compared to existing therapy requiring intramuscular injections of the gonadotropins. The authors are from multiple hospitals in Spain.


Patient selection: male with hypogonadotropic hypogonadism with azoospermia or aspermia from 18 to 45 years of age


Problems with therapy of hypogonadotropic hypogonadism:

(1) requires frequent injections

(2) response to therapy may take weeks or months


Benefits of subcutaneous injections:

(1) less pain

(2) greater convenience (no need to travel to a clinic 3 times a week)

(3) less time involved

(4) cheaper administration costs (purified drug might be more expensive)

(5) better compliance

(6) less erratic serum levels


All of these features result in better therapeutic outcomes.


To read more or access our algorithms and calculators, please log in or register.